One-year results from a head-to-head trial comparing ixekizumab (Taltz) and adalimumab (Humira) in patients with active PsA will help clinicians make evidence based treatment decisions, researchers say. The phase IIIb/IV multicentre SPIRIT-H2H trial included 566 patients who were randomised to receive the interleukin 17A targeted antibody ixekizumab (n=246) or TNF inhibitor adalimumab (n=237). Patients received ...
Benefits of ixekizumab in PsA maintained at one year: SPIRIT-H2H
By Nicola Garrett
14 Jul 2020